Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API
Jinyao Pharmaceutical (SHA:600488) has obtained a DMF or drug master files letter from the US Food and Drug Administration for its Deflazacort API, according to a Wednesday filing on the Shanghai Stock Exchange.
Deflazacort is an active pharmaceutical ingredient widely used to treat Duchenne muscular dystrophy. The global market for Deflazacort preparations is estimated to have reached $106 million in 2023, Jinyao said.
The FDA's approval of Jinyao Pharmaceuticals' DMF indicates that the company's Deflazacort API meets the quality standards required for use in the US.
Price (RMB): ¥3.78, Change: ¥-0.020, Percent Change: -0.53%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。